Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU1-108P is classified as a **pseudogene** of the U1 small nuclear RNA family. Pseudogenes are nonfunctional DNA segments that closely resemble known genes but typically lack protein-coding potential or usual biological activity[4]. In the case of U1 snRNA pseudogenes—including RNU1-108P—they are derived from or highly similar to the canonical U1 small nuclear RNA gene, a component of the **spliceosome** involved in pre-mRNA splicing[1][3]. While canonical U1 snRNA genes are essential for gene expression regulation and transcriptome integrity, pseudogenes like RNU1-108P are generally not considered functional, although emerging research suggests some pseudogenes may be transcribed and could exert regulatory effects in rare cases[3][4]. However, there is no evidence that RNU1-108P itself encodes a functional molecule, serves as a therapeutic target, or has clinical relevance as a biomarker or drug target. It is also not a receptor, enzyme, transporter, or similar therapeutic entity[3][4]. **Summary of rationale for key decisions:** - **is_target:** false — RNU1-108P is a pseudogene and not a validated or recognized therapeutic target. - **is_incorrect:** true — The target is not functional or actionable for therapeutic development and lacks specific biological or clinical roles. This is not a receptor, enzyme, transporter, or disease-linked molecule. - **molecular_classifications:** Classified under "Other" to signify its nature as a non-coding RNA pseudogene, not belonging to standard therapeutic target classes. - **disease_roles/biomarkers:** No evidence for clinical association or biomarker role specific to RNU1-108P; general pseudogene roles in cancer or other diseases noted in broad literature but not for this specific pseudogene[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 108, pseudogene (RNU1-108P).